Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06592703 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells for the Treatment of Primary Progressive Multiple Sclerosis

Study acronym: MAESTRO-4MS
StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site details revised at 2 of 2 sitesv4
  2. Trial status: Active, Not Recruiting to Recruitingv3 Show 4 more changesShow less
    • Primary completion date: Jun 2028 to Dec 2029
    • Start date: Dec 16, 2024 to Mar 6, 2025
    • Study completion date: Dec 2028 to Dec 2029
    • Site details revised at 2 of 2 sites
  3. Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Start date changed from estimate of Oct 2024 to Dec 16, 2024
    • Site contacts updated at 2 of 2 sites
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
In this study, we propose, for the first time, to test the safety and the potential efficacy of repeated allogenic Adipose tissue-derived Mesenchymal Stromal Cells IT injections in Primary Progressive Multiple Sclerosis patients.
Trial Details
NCT Number NCT06592703
Lead Sponsor Rennes University Hospital
Collaborators: Etablissement Français du Sang
Conditions
(from sponsor)		 Multiple Sclerosis
Related terms Multiple Sclerosis
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov